Have a feature idea you'd love to see implemented?
Let us know!
ZLAB Zai Lab Ltd
Price (delayed)
$31.22
Market cap
$3.11B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3
Enterprise value
$2.46B
Zai Lab ) is an innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, infectious and autoimmune diseases to patients in China and around the world. To
Highlights
Zai Lab's revenue has increased by 28% YoY and by 11% from the previous quarter
The EPS has grown by 27% YoY and by 14% from the previous quarter
The quick ratio has dropped by 55% year-on-year and by 25% since the previous quarter
The debt has grown by 32% from the previous quarter
Key stats
What are the main financial stats of ZLAB
Market
Valuations
Earnings
Shares outstanding
99.61M
Market cap
$3.11B
Enterprise value
$2.46B
Price to earnings (P/E)
N/A
Price to book (P/B)
4.4
Price to sales (P/S)
9.44
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.63
Revenue
$322.71M
EBIT
-$297.72M
EBITDA
-$278.93M
Free cash flow
-$202.23M
Per share
Balance sheet
Liquidity
EPS
-$3
Free cash flow per share
-$2.07
Book value per share
$7.1
Revenue per share
$3.31
TBVPS
$9.63
Total assets
$987.37M
Total liabilities
$283.19M
Debt
$83.68M
Equity
$704.18M
Working capital
$618.21M
Debt to equity
0.12
Current ratio
3.46
Quick ratio
3.21
Net debt/EBITDA
2.32
Margins
Efficiency
Dividend
EBITDA margin
-86.4%
Gross margin
62.9%
Net margin
-92.4%
Operating margin
-107.3%
Return on assets
-29.4%
Return on equity
-38%
Return on invested capital
-372.7%
Return on capital employed
-40.5%
Return on sales
-92.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ZLAB stock price
How has the Zai Lab stock price performed over time
Intraday
-0.67%
1 week
7.88%
1 month
29.33%
1 year
22.96%
YTD
14.23%
QTD
29.33%
Financial performance
How have Zai Lab's revenue and profit performed over time
Revenue
$322.71M
Gross profit
$203.14M
Operating income
-$346.33M
Net income
-$298.33M
Gross margin
62.9%
Net margin
-92.4%
The net margin has grown by 41% YoY and by 21% from the previous quarter
Zai Lab's revenue has increased by 28% YoY and by 11% from the previous quarter
The company's operating margin rose by 27% YoY and by 11% QoQ
The company's net income rose by 24% YoY and by 12% QoQ
Growth
What is Zai Lab's growth rate over time
Valuation
What is Zai Lab stock price valuation
P/E
N/A
P/B
4.4
P/S
9.44
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.63
The EPS has grown by 27% YoY and by 14% from the previous quarter
The stock's P/B is 64% above its last 4 quarters average of 2.7 but 16% below its 5-year quarterly average of 5.3
The equity has contracted by 24% YoY and by 8% from the previous quarter
ZLAB's price to sales (P/S) is 88% lower than its 5-year quarterly average of 79.7 but 28% higher than its last 4 quarters average of 7.4
Zai Lab's revenue has increased by 28% YoY and by 11% from the previous quarter
Efficiency
How efficient is Zai Lab business performance
The ROS has grown by 41% YoY and by 21% from the previous quarter
Zai Lab's return on invested capital has decreased by 11% QoQ
The ROA has grown by 10% YoY and by 10% from the previous quarter
ZLAB's ROE is up by 5% QoQ
Dividends
What is ZLAB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ZLAB.
Financial health
How did Zai Lab financials performed over time
The company's total liabilities has surged by 63% YoY and by 25% QoQ
The quick ratio has dropped by 55% year-on-year and by 25% since the previous quarter
The debt is 88% less than the equity
Zai Lab's debt to equity has soared by 50% from the previous quarter
The debt has grown by 32% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.